Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

L-Arginine Improves Cognitive Impairment in Hypertensive Frail Older Adults.

  • 2022-04-12
  • Frontiers in cardiovascular medicine 9
    • Pasquale Mone
    • Antonella Pansini
    • Stanislovas S Jankauskas
    • Fahimeh Varzideh
    • Urna Kansakar
    • Angela Lombardi
    • Valentina Trimarco
    • Salvatore Frullone
    • Gaetano Santulli

Study Design

Type
Clinical Trial
Population
35 frail hypertensive elderly patients assigned to L-Arginine and 37 assigned to placebo
Methods
clinical trial, 4-weeks oral supplementation of L-Arginine vs placebo
Blinding
Double-blind
Duration
4 weeks
Funding
Unclear
Cognitive impairment is a prevailing event in hypertensive patients and in frail older adults. Endothelial dysfunction has been shown to underlie both hypertension and cognitive dysfunction. Our hypothesis is that L-Arginine, which is known to ameliorate endothelial dysfunction, could counteract cognitive impairment in a high-risk population of hypertensive frail older adults. We designed a clinical trial to verify the effects of 4-weeks oral supplementation of L-Arginine on global cognitive function of hypertensive frail older patients. The study was successfully completed by 35 frail hypertensive elderly patients assigned to L-Arginine and 37 assigned to placebo. At follow-up, we found a significant difference in the Montreal Cognitive Assessment (MoCA) test score between the L-Arginine treated group and placebo (p: 0.0178). Moreover, we demonstrated that L-Arginine significantly attenuates Angiotensin II-induced mitochondrial oxidative stress in human endothelial cells. In conclusion, our findings indicate for the first time that oral L-Arginine supplementation significantly improves cognitive impairment in frail hypertensive older adults.

Clinical trial registration

www.ClinicalTrials.gov, identifier: NCT04962841.

Research Insights

  • L-Arginine→Improved Global Cognitive Function

    At follow-up, we found a significant difference in the Montreal Cognitive Assessment (MoCA) test score between the L-Arginine treated group and placebo (p: 0.0178).

    Effect
    Beneficial
    Effect size
    Small
Back to top